NCJ Number
192560
Journal
Journal of Psychoactive Drugs Volume: 33 Issue: 3 Dated: September 2001 Pages: 213-221
Date Published
September 2001
Length
9 pages
Annotation
In examining the historical aspects of both 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and 3,4-methylenedioxyamphetamine (MDA), controversies have arisen from their dangerous neurotoxins to their potential use as psychotherapeutics.
Abstract
Both 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy") and 3,4-methylenedioxyamphetamine (MDA) are compounds classified as Schedule 1 substances, an illicit drug. Both compounds date back to the early 1900's, and the dangers involved in consuming MDMA and MDA have been the subject of heated debate for the last decade. Their classification as illicit, controlled substances has neither prevented nor contained their use. MDMA is one of the most popular substances used recreationally in North America. A review of history suggests that these compounds have the potential to be used safely as possible psychotherapeutic tools. However, the legal status of MDMA and MDA prevents their psychotherapeutic use. This suggests the potential reconsideration of MDMA and MDA's legal status. Current clinical trials in Spain and Israel in the use of MDMA in treating posttraumatic stress disorder may aid in the removal of MDMA from its restricting Schedule 1 status. References